{"id":5404,"date":"2025-12-27T16:26:26","date_gmt":"2025-12-27T13:26:26","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5404"},"modified":"2025-12-27T17:01:50","modified_gmt":"2025-12-27T14:01:50","slug":"one-time-gene-therapies-or-exon-skipping-therapies-which-may-be-better-for-duchenne-muscular-dystrophy-dmd-today","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/one-time-gene-therapies-or-exon-skipping-therapies-which-may-be-better-for-duchenne-muscular-dystrophy-dmd-today\/","title":{"rendered":"\u2018'Tek Seferlik' Gen Terapileri mi Yoksa Ekzon Atlama Terapileri mi: G\u00fcn\u00fcm\u00fczde Duchenne Hastal\u0131\u011f\u0131 \u0130\u00e7in Hangisi Daha \u0130yi Olabilir?"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Ekzon atlama, Duchenne kas distrofisi (DMD) i\u00e7in \u00f6nde gelen bir tedavi yakla\u015f\u0131m\u0131d\u0131r. DMD, genellikle translasyon okuma \u00e7er\u00e7evesini bozan DMD genindeki patojenik varyantlardan kaynaklanan ilerleyici bir kas erimesi bozuklu\u011fudur. Bu yakla\u015f\u0131m, transkripti yeniden \u00e7er\u00e7evelemek ve i\u00e7sel olarak silinmi\u015f ancak k\u0131smen i\u015flevsel bir quasi-distrofin proteini \u00fcretmek i\u00e7in DMD pre-mRNA&#039;s\u0131n\u0131n eklenmesini d\u00fczenlemeyi ama\u00e7lar. <strong>Daha fazla bilgi edin<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" data-type=\"post\" data-id=\"1445\" rel=\"noreferrer noopener\">Ekzon atlama nedir?<\/a><\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#fda-approved-exon-skipping-therapies-clinical-efficacy-is-quite-limited\">FDA onayl\u0131 ekzon atlama terapilerinin klinik etkinli\u011fi \u00e7ok s\u0131n\u0131rl\u0131d\u0131r<\/a><\/li><li><a href=\"#in-individuals-affected-by-dmd-initiating-exon-skipping-therapies-early-increases-their-effectiveness\">DMD'den etkilenen bireylerde, ekzon atlama tedavilerine erken ba\u015flanmas\u0131, tedavilerin etkinli\u011fini art\u0131r\u0131r<\/a><\/li><li><a href=\"#fda-approved-dmd-therapies-have-limited-effectiveness-and-are-very-expensive\">FDA onayl\u0131 DMD tedavilerinin etkinli\u011fi s\u0131n\u0131rl\u0131d\u0131r ve \u00e7ok pahal\u0131d\u0131r<\/a><\/li><li><a href=\"#what-is-the-difference-between-pm-os-and-ppm-os\">PMO&#039;lar ve PPMO&#039;lar aras\u0131ndaki fark nedir?<\/a><\/li><li><a href=\"#what-is-an-mdx-mouse-and-what-are-its-features\">MDX fare nedir ve \u00f6zellikleri nelerdir?<\/a><\/li><li><a href=\"#efficacy-of-dystrophin-restoration-therapies\">Distrofin restorasyon tedavilerinin etkinli\u011fi<\/a><ul><li><a href=\"#the-total-amount-of-dystrophin-restored\">Geri kazand\u0131r\u0131lan toplam distrofin miktar\u0131.<\/a><\/li><li><a href=\"#the-quality-of-dystrophin-restored\">Distrofinin kalitesinin yeniden sa\u011flanmas\u0131.<\/a><\/li><li><a href=\"#correct-localization-of-dystrophin-at-the-sarcolemma\">Distrofinin sarkolemmada do\u011fru lokalizasyonu.<\/a><\/li><li><a href=\"#optimal-timing-for-initiation-of-treatment\">Tedaviye ba\u015flama i\u00e7in en uygun zamanlama.<\/a><\/li><\/ul><\/li><li><a href=\"#exon-skipping-therapies-may-also-be-implemented-as-part-of-a-combination-therapy\">Ekzon atlama terapileri, kombine tedavinin bir par\u00e7as\u0131 olarak da uygulanabilir<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"fda-approved-exon-skipping-therapies-clinical-efficacy-is-quite-limited\">FDA onayl\u0131 ekzon atlama terapilerinin klinik etkinli\u011fi \u00e7ok s\u0131n\u0131rl\u0131d\u0131r<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fmada, FDA onayl\u0131 d\u00f6rt ekzon atlama terapisi ele al\u0131nm\u0131\u015f ve bunlar\u0131n klinik etkinli\u011finin olduk\u00e7a s\u0131n\u0131rl\u0131 oldu\u011fu a\u00e7\u0131k\u00e7a belirtilmi\u015ftir.<\/strong> Tedavi zamanlamas\u0131n\u0131n ekzon atlama sonu\u00e7lar\u0131n\u0131 nas\u0131l etkiledi\u011fini ara\u015ft\u0131rmak amac\u0131yla, bu bilimsel \u00e7al\u0131\u015fmada, yeti\u015fkin (12 hafta) veya ya\u015fl\u0131 (75 hafta) evrelerden ba\u015flayarak, distrofin eksikli\u011fi olan mdx farelerine peptit-fosforodiamidat morfolino oligon\u00fckleotid (PPMO) ekzon atlama konjugatlar\u0131 enjekte edildi ve biyokimyasal ve transkriptomik analizler i\u00e7in tibialis anterior kas dokusu topland\u0131.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"in-individuals-affected-by-dmd-initiating-exon-skipping-therapies-early-increases-their-effectiveness\">DMD'den etkilenen bireylerde, ekzon atlama tedavilerine erken ba\u015flanmas\u0131, tedavilerin etkinli\u011fini art\u0131r\u0131r<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PPMO ile tedavi edilen yeti\u015fkinlerdeki ortalama Dmd ekzon 23 atlamas\u0131 79% iken, ya\u015fl\u0131 PPMO ile tedavi edilen mdx farelerinde 44% idi; buna kar\u015f\u0131l\u0131k distrofin protein restorasyonu s\u0131ras\u0131yla 35% ve 8% idi. Histopatolojik iyile\u015fmeler yaln\u0131zca yeti\u015fkinlerde tedavi edilen farelerde belirgindi.<\/strong> Yeti\u015fkin mdx farelerinde PPMO tedavisi, geni\u015f \u00e7apl\u0131 bir transkriptomik kaymaya ve vah\u015fi tip imzas\u0131na do\u011fru bir e\u011filime neden olurken, ya\u015fl\u0131 farelerdeki tedavi ihmal edilebilir gen ekspresyon de\u011fi\u015fikliklerine yol a\u00e7t\u0131; bu da ge\u00e7 m\u00fcdahalenin, d\u00fc\u015f\u00fck seviyede distrofin restorasyonuna ra\u011fmen hastal\u0131kla ili\u015fkili patolojileri tersine \u00e7evirmede etkisiz oldu\u011funu g\u00f6stermektedir. Distrofin transkript dengesizli\u011fi yaln\u0131zca yeti\u015fkin tedavi g\u00f6ren mdx farelerinde d\u00fczeltildi. Ya\u015fl\u0131 mdx kas\u0131nda daha g\u00fc\u00e7l\u00fc bir \u015fekilde yukar\u0131 reg\u00fcle edilen distrofin bask\u0131lay\u0131c\u0131 mikroRNA miR-31-5p&#039;nin artm\u0131\u015f ekspresyonu, potansiyel bir mekanistik a\u00e7\u0131klama sa\u011flamaktad\u0131r. <strong>Sonu\u00e7 olarak, PPMO arac\u0131l\u0131 ekzon atlama, ya\u015fl\u0131 distrofik kaslara k\u0131yasla yeti\u015fkin distrofik kaslarda ba\u015flat\u0131ld\u0131\u011f\u0131nda \u00f6nemli \u00f6l\u00e7\u00fcde daha etkilidir ve bu da DMD'den etkilenen bireylerde erken tedavi m\u00fcdahalesini desteklemektedir.<\/strong> &gt;&gt; <strong>Daha fazla bilgi edin<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/Duchenne-Population-Potentially-Amenable-to-Exon-Skipping-01.04.25.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Ekzon Atlamaya Uygun Potansiyel Duchenne Pop\u00fclasyonu<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"fda-approved-dmd-therapies-have-limited-effectiveness-and-are-very-expensive\">FDA onayl\u0131 DMD tedavilerinin etkinli\u011fi s\u0131n\u0131rl\u0131d\u0131r ve \u00e7ok pahal\u0131d\u0131r<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Son y\u0131llarda DMD i\u00e7in deneysel tedaviler alan\u0131nda \u00f6nemli ilerlemeler kaydedilmi\u015ftir. Distrofinin yeniden olu\u015fturulmas\u0131 i\u00e7in \u00e7e\u015fitli stratejiler kullan\u0131lm\u0131\u015ft\u0131r. \u00d6rne\u011fin, antisens oligon\u00fckleotid (ASO) arac\u0131l\u0131 ekzon atlama, distrofin translasyon okuma \u00e7er\u00e7evesinin yeniden olu\u015fturulmas\u0131 i\u00e7in alternatif eklemeyi d\u00fczenlemek amac\u0131yla kullan\u0131labilir. <strong>Bu t\u00fcrden d\u00f6rt antisens oligon\u00fckleotid ila\u00e7, DMD&#039;li erkek \u00e7ocuklar\u0131n tedavisi i\u00e7in ABD&#039;den h\u0131zland\u0131r\u0131lm\u0131\u015f onay ald\u0131 (Eteplirsen, Viltolarsen, Golodiresen ve Casimersen). DMD ara\u015ft\u0131rmalar\u0131 ve hasta topluluklar\u0131 i\u00e7in b\u00fcy\u00fck bir ba\u015far\u0131 olsa da, bu bile\u015fiklerin sa\u011flad\u0131\u011f\u0131 distrofin restorasyonu minimal d\u00fczeydedir ve klinik faydas\u0131 tart\u0131\u015fmal\u0131d\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Benzer \u015fekilde, FDA, Faz 3 denemesinde klinik hedefine ula\u015famamas\u0131na ra\u011fmen, 2023 y\u0131l\u0131nda DMD i\u00e7in ilk gen terapisi olan Elevidys&#039;yi onaylad\u0131. Dahas\u0131, Elevidys&#039;nin (ve genel olarak y\u00fcksek doz adeno-ili\u015fkili vir\u00fcs tabanl\u0131 gen terapilerinin) g\u00fcvenli\u011fi, \u00e7ok say\u0131da hasta \u00f6l\u00fcm\u00fcn\u00fcn ard\u0131ndan sorgulanmaya ba\u015fland\u0131. <strong>Daha Fazlas\u0131n\u0131 Ke\u015ffedin:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/tr\/why-elevidys-was-not-approved-by-the-european-medicines-agency-ema\/\" target=\"_blank\" rel=\"noreferrer noopener\">Elevidys Neden Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) Taraf\u0131ndan Onaylanmad\u0131?<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-the-difference-between-pm-os-and-ppm-os\">PMO&#039;lar ve PPMO&#039;lar aras\u0131ndaki fark nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Mevcut ekzon atlama ASO'lar\u0131n\u0131n tamam\u0131 fosforodiamidat morfolino oligon\u00fckleotidlerdir (PMO'lar). Bu kimya do\u011fada bulunmaz ve yayg\u0131n olarak g\u00fcvenli kabul edilir. Bununla birlikte, PMO'lar\u0131n iskelet (ve \u00f6zellikle kalp) kas\u0131na iletimi \u00e7ok s\u0131n\u0131rl\u0131d\u0131r; bu da aktivitelerini art\u0131rabilecek iletimi destekleyici bile\u015fenlerin aranmas\u0131na yol a\u00e7m\u0131\u015ft\u0131r. Bilim insanlar\u0131, bu ama\u00e7lar i\u00e7in peptit konjugeli PMO'lar\u0131n (PPMO'lar) kullan\u0131m\u0131n\u0131 kapsaml\u0131 bir \u015fekilde ara\u015ft\u0131rm\u0131\u015flard\u0131r. <strong>PPMO'lar, konjuge edilmemi\u015f PMO'lardan \u00e7ok daha etkilidir ve kalp dokusunda ekzon atlama aktivitesi g\u00f6sterirler.<\/strong> PPMO&#039;lar \u015fu anda PepGen Ltd ve Entrada Therapeutics taraf\u0131ndan ticari olarak geli\u015ftirilmektedir. Benzer \u015fekilde, Avidity Biosciences ve Dyne Therapeutics, DMD i\u00e7in PMO antikor ve PMO-FAb fragman terap\u00f6tikleri geli\u015ftirmektedir. <strong>Devam\u0131n\u0131 oku<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/next-generation-exon-skipping-therapies-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Yeni Nesil Ekzon Atlama Terapileri<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-an-mdx-mouse-and-what-are-its-features\">MDX fare nedir ve \u00f6zellikleri nelerdir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mdx faresi, DMD&#039;nin en yayg\u0131n kullan\u0131lan fare modelidir ve Dmd ekzon 23&#039;te erken sonlanma kodonu ta\u015f\u0131r; bu kodonun atlanmas\u0131, DMD patolojisinin baz\u0131 y\u00f6nlerini g\u00f6steren X&#039;e ba\u011fl\u0131 kas distrofisine yol a\u00e7ar.<\/strong> Bu \u00e7al\u0131\u015fmada bilim insanlar\u0131 daha \u00f6nce bu farede distrofin restorasyon terapilerinin etkilerine odaklanarak \u00e7e\u015fitli omik analizler ger\u00e7ekle\u015ftirmi\u015flerdir; bunlar aras\u0131nda gen ekspresyonu\/mikroRNA mikrodizi, k\u00fc\u00e7\u00fck RNA-Seq ve y\u00fcksek \u00e7\u00f6z\u00fcn\u00fcrl\u00fckl\u00fc k\u00fctle spektrometrisi tabanl\u0131 proteomik analizler yer almaktad\u0131r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"efficacy-of-dystrophin-restoration-therapies\">Distrofin restorasyon tedavilerinin etkinli\u011fi<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"the-total-amount-of-dystrophin-restored\">Geri kazand\u0131r\u0131lan toplam distrofin miktar\u0131.<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Genel kabul g\u00f6ren g\u00f6r\u00fc\u015fe g\u00f6re, ne kadar \u00e7ok distrofin geri kazand\u0131r\u0131labilirse o kadar iyidir. \u00c7e\u015fitli kan\u0131tlar, sa\u011fl\u0131kl\u0131 distrofin seviyelerinin ~10%&#039;sinin terap\u00f6tik fayda i\u00e7in makul bir e\u015fik oldu\u011funu g\u00f6stermektedir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"the-quality-of-dystrophin-restored\">Distrofinin kalitesinin yeniden sa\u011flanmas\u0131.<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon atlamal\u0131 ekleme d\u00fczeltmesi ve mikrodistrofin gen terapileri, her ikisi de baz\u0131 Becker kas distrofisi hastalar\u0131nda bulunanlara benzeyen ve hafif patolojiyle ili\u015fkili olan, i\u00e7ten silinmi\u015f yar\u0131-distrofin proteinlerinin \u00fcretimine dayanmaktad\u0131r. <strong>Ancak, bu t\u00fcr yar\u0131-distrofinlerin, tam uzunluktaki distrofin proteininin kayb\u0131n\u0131 tamamen telafi etmesi olas\u0131 de\u011fildir. Tam uzunluktaki distrofinlerin arzu edilir oldu\u011fu giderek daha fazla kabul g\u00f6rmektedir; bu da distrofin ORF&#039;sinin boyutunun (~11 kb), AAV vekt\u00f6rlerinin paketleme kapasitesini (~4,6 kb) a\u015fmas\u0131 nedeniyle bir zorluk te\u015fkil etmektedir.<\/strong> DMD ekzon 2 duplikasyonunu tedavi etmek i\u00e7in ekzon atlama terapisi uygulanan insan klinik deneme kat\u0131l\u0131mc\u0131lar\u0131nda tam uzunlukta distrofinin restorasyonu g\u00f6sterilmi\u015ftir. Ayr\u0131ca, b\u00f6l\u00fcnm\u00fc\u015f vekt\u00f6r yakla\u015f\u0131mlar\u0131 veya daha y\u00fcksek paketleme kapasitesine sahip vekt\u00f6rler kullan\u0131larak tam uzunlukta distrofin da\u011f\u0131t\u0131m stratejileri geli\u015ftirmeye y\u00f6nelik bir\u00e7ok ba\u015fka \u00e7al\u0131\u015fma da mevcuttur.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"correct-localization-of-dystrophin-at-the-sarcolemma\">Distrofinin sarkolemmada do\u011fru lokalizasyonu.<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00e7al\u0131\u015fma, kas lifi i\u00e7indeki sarkolemma boyunca distrofin proteininin homojen da\u011f\u0131l\u0131m\u0131n\u0131n, tedavi ba\u015far\u0131s\u0131n\u0131n \u00f6nemli bir belirleyicisi oldu\u011funu g\u00f6stermi\u015ftir. \u00d6nemli olarak, PPMO konjugatlar\u0131 ile ekzon atlama tedavisi, sarkolemmal distrofin \u00f6rt\u00fcs\u00fcn\u00fcn homojen bir modelini (d\u00fc\u015f\u00fck dozlarda bile) ind\u00fcklerken, CRISPR-Cas9 arac\u0131l\u0131 ekzon silme i\u015flemi, distrofin da\u011f\u0131l\u0131m\u0131nda d\u00fczensiz bir modele neden olmu\u015ftur. Bu \u00f6nemli bir g\u00f6zlemdir, \u00e7\u00fcnk\u00fc eksik sarkolemmal distrofin \u00f6rt\u00fcs\u00fcn\u00fcn, kas lifi yenilenmesini \u00f6nlemek ve hastal\u0131k patolojisini d\u00fczeltmek i\u00e7in yetersiz olmas\u0131 muhtemeldir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"optimal-timing-for-initiation-of-treatment\">Tedaviye ba\u015flama i\u00e7in en uygun zamanlama.<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Distrofin restorasyon tedavilerinin erken ba\u015flat\u0131lmas\u0131, kas\u0131n patolojik dejenerasyonunu \u00f6nlemek veya geciktirmek a\u00e7\u0131s\u0131ndan faydal\u0131 olabilir. <strong>Ancak, mikrodistrofin gen terapisi veya CRISPR-Cas9 arac\u0131l\u0131 gen d\u00fczeltmesi gibi &#039;tek seferlik&#039; tedavilerde, d\u00fczeltilmemi\u015f miyon\u00fckleuslar\u0131n b\u00fcy\u00fcme ve yenilenme sonucu miyofiberlere eklenmesiyle d\u00fczeltilmi\u015f n\u00fckleus say\u0131s\u0131 giderek azalacakt\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00e7al\u0131\u015fmada, bilim insanlar\u0131, tedaviye yeti\u015fkin ve ya\u015fl\u0131 bireylerde ba\u015fland\u0131\u011f\u0131nda PPMO antisens oligon\u00fckleotid konjugatlar\u0131 kullan\u0131larak ekzon atlama y\u00f6nteminin etkinli\u011fini de\u011ferlendirdiler. <strong>Bu veriler, DMD tedavisinde erken tedavinin faydal\u0131 olabilece\u011fi fikrini desteklemektedir.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"exon-skipping-therapies-may-also-be-implemented-as-part-of-a-combination-therapy\">Ekzon atlama terapileri, kombine tedavinin bir par\u00e7as\u0131 olarak da uygulanabilir<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ekzon atlama terapisi, gen\u00e7 DMD'li erkek \u00e7ocuklarda, gen terapisi ile tedavi g\u00fcvenli ve uygun hale gelene kadar kas fonksiyonlar\u0131n\u0131 korumak amac\u0131yla ba\u015flat\u0131labilir.<\/strong> Nitekim, preklinik kan\u0131tlar, PMO arac\u0131l\u0131 ekzon atlaman\u0131n AAV-U7 arac\u0131l\u0131 ekzon atlama veya AAV-mikrodistrofin gen terapisi ile birle\u015ftirilmesinin sinerjik bir etkiye sahip oldu\u011funu desteklemektedir. Bu \u00e7al\u0131\u015fma, DMD hastalar\u0131nda ekzon atlama tedavisine ba\u015flama i\u00e7in uygun zaman konusundaki tart\u0131\u015fmaya katk\u0131da bulunmaktad\u0131r. <strong>Burada sunulan preklinik verilerden elde edilen kan\u0131tlar, ileri doku patolojisi olu\u015fmadan \u00f6nce, erken ya\u015fta ekzon atlama tedavisinin ba\u015flat\u0131lmas\u0131 fikrini desteklemektedir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Okumaya devam edin:<\/strong> <a href=\"https:\/\/www.biorxiv.org\/content\/10.64898\/2025.12.23.696144v1.full.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Zamanlama \u00f6nemlidir: Duchenne kas distrofisi fare modelinde ekzon atlama terapisi, erken d\u00f6nemde ba\u015flat\u0131ld\u0131\u011f\u0131nda en etkili sonu\u00e7lar\u0131 vermektedir.<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Exon skipping is a leading therapeutic approach for Duchenne muscular dystrophy (DMD), aprogressive muscle wasting disorder caused by pathogenic variants in the DMD gene that typically disrupt the translation reading frame. This approach aims to modulate DMD pre-mRNA splicing to reframe the transcript and generate an internally deleted but partially functional quasi-dystrophin protein. >> Learn [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5418,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[282],"tags":[473,119,77,178,61,472,268,471],"class_list":["post-5404","post","type-post","status-publish","format-standard","has-post-thumbnail","category-editorials","tag-casimersen","tag-eteplirsen","tag-exon-skipping","tag-exon-skipping-therapies","tag-gene-therapy","tag-golodiresen","tag-microrna","tag-viltolarsen"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5404"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5404\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5418"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}